What problem is your work helping to solve?
Age related Macular Degeneration (AMD) is the leading cause of irreversible blindness in the elderly, affecting ~8.7% of the worldwide population. Our work is trying to identify key disease mechanisms and develop novel therapies for this devastating blinding disease.
What solution are your working toward and why is it innovative?
Our solution is to develop safer but superior agents to anti-VEGF antibodies, which are the current mainstay for treating wet AMD. We will use the cutting-edge CRISPR genome editing technology to drive inducible VEGF inhibition in the eye, therefore avoiding the undesirable effects caused by long term VEGF inhibition and repetitive intraocular injections.
What applications does your research have for Tulane entrepreneurs and the broader business community?
We are extremely excited about the opportunity to develop solutions for the major disease AMD, and will be glad to work with Tulane entrepreneurs and the business community to deliver it to the market place.